NZ515061A - Use of a cyclic compound in cell cycling - Google Patents

Use of a cyclic compound in cell cycling

Info

Publication number
NZ515061A
NZ515061A NZ515061A NZ51506100A NZ515061A NZ 515061 A NZ515061 A NZ 515061A NZ 515061 A NZ515061 A NZ 515061A NZ 51506100 A NZ51506100 A NZ 51506100A NZ 515061 A NZ515061 A NZ 515061A
Authority
NZ
New Zealand
Prior art keywords
group
cells
hydrocarbyl
compound
use according
Prior art date
Application number
NZ515061A
Other languages
English (en)
Inventor
Michael John Reed
Barry Victor Lloyd Potter
Original Assignee
Sterix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9910166.9A external-priority patent/GB9910166D0/en
Priority claimed from GB0002113A external-priority patent/GB0002113D0/en
Application filed by Sterix Ltd filed Critical Sterix Ltd
Publication of NZ515061A publication Critical patent/NZ515061A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NZ515061A 1999-04-30 2000-04-28 Use of a cyclic compound in cell cycling NZ515061A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9910166.9A GB9910166D0 (en) 1999-04-30 1999-04-30 Use
US13952099P 1999-06-16 1999-06-16
GB0002113A GB0002113D0 (en) 2000-01-28 2000-01-28 Use
PCT/GB2000/001661 WO2000066095A2 (en) 1999-04-30 2000-04-28 Use of estrone derivatives as antitumour agents

Publications (1)

Publication Number Publication Date
NZ515061A true NZ515061A (en) 2004-04-30

Family

ID=27255503

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515061A NZ515061A (en) 1999-04-30 2000-04-28 Use of a cyclic compound in cell cycling

Country Status (7)

Country Link
US (1) US8207152B2 (enExample)
EP (1) EP1173182A2 (enExample)
JP (1) JP5042411B2 (enExample)
AU (1) AU783910B2 (enExample)
IL (2) IL145995A0 (enExample)
NZ (1) NZ515061A (enExample)
WO (1) WO2000066095A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040127473A1 (en) * 1996-12-05 2004-07-01 Reed Michael John Compound
GB9913536D0 (en) * 1999-06-10 1999-08-11 Sterix Ltd Use
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US20020106348A1 (en) * 2000-07-12 2002-08-08 Peng Huang Cancer therapeutics involving the administration of 2-methoxyestradiol and an agent that increases intracellular superoxide anion
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
AU8838601A (en) * 2000-11-27 2002-06-03 Entremed Inc Antiangiogenic agents
GB0113920D0 (en) 2001-06-07 2001-08-01 Sterix Ltd Composition
DE10139494A1 (de) * 2001-08-13 2003-03-06 Jenapharm Gmbh Antitumor wirksame 2-Alkoxyestradiolsulfamate
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
ATE317369T1 (de) * 2001-12-21 2006-02-15 Schering Ag Industriell anwendbares verfahren zur sulfamoylation von alkoholen und von phenolen
GB0306717D0 (en) * 2003-03-24 2003-04-30 Sterix Ltd Compound
AU2004224053B2 (en) * 2003-03-24 2011-06-09 Sterix Limited Oestrogen derivatives as inhibitors of steroid sulphatase
WO2005030120A2 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
EP1756139A4 (en) 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
GB0421106D0 (en) * 2004-09-22 2004-10-27 Sterix Ltd Compound
CA2646065C (en) 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2023105303A1 (en) * 2021-12-06 2023-06-15 Kashiv Biosciences, Llc Compounds for the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003939D0 (en) * 1990-02-21 1990-04-18 Imperial College Sulphatase inhibitors
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
GB9625334D0 (en) * 1996-12-05 1997-01-22 Imperial College Compound
US6083978A (en) 1996-03-05 2000-07-04 Sterix Limited Compounds with a sulfamate group
GB9118478D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
GB9603325D0 (en) 1996-02-16 1996-04-17 Imperial College A compound
GB9118465D0 (en) * 1991-08-29 1991-10-16 Imperial College Steroid sulphatase inhibitors
US6087347A (en) 1996-09-12 2000-07-11 Teikoku Hormone Mfg. Co., Ltd. 3-substituted-D-homo-1,3,5(10)-estratriene derivatives
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
US5880115A (en) 1997-07-18 1999-03-09 Duquesne University Of The Holy Ghost Steroid sulfatase inhibitors and methods for making and using the same
GB2331987B (en) * 1997-12-04 2002-11-27 Imperial College Polycyclic sulphamate inhibitors of oestrone sulphatase
GB2331988B (en) * 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
ATE401896T1 (de) * 1998-06-10 2008-08-15 Sterix Ltd Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
GB9913536D0 (en) * 1999-06-10 1999-08-11 Sterix Ltd Use
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies

Also Published As

Publication number Publication date
EP1173182A2 (en) 2002-01-23
IL145995A (en) 2009-11-18
US8207152B2 (en) 2012-06-26
JP2002543114A (ja) 2002-12-17
WO2000066095A2 (en) 2000-11-09
AU783910B2 (en) 2005-12-22
AU4766800A (en) 2000-11-17
IL145995A0 (en) 2002-07-25
WO2000066095A3 (en) 2001-08-09
JP5042411B2 (ja) 2012-10-03
US20060122161A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
AU783910B2 (en) Use of estrone derivatives as antitumour agents
CA2334119C (en) Pharmaceutical composition with tumor necrosis factor a and 2-methoxyestrone-3-o-sulphamate for inhibition of estrone sulphatase
EP0942919B1 (en) Sulphatase Inhibitors
US20020193444A1 (en) Composition
US20030225051A1 (en) Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
US20040009959A1 (en) Thioether sulphamate steroids as steroid inhibtors and anti-cancer compounds
US20070225256A1 (en) Compound
GB2331988A (en) Polycyclic sulphamate inhibitors of oestrone sulphatase
EP1237902B1 (en) Halogenated sulphamate-, phosphonate-, thiophosphonate-, sulphonate- and sulphonamide- compounds as inhibitors of steroid sulphatase
JP5144543B2 (ja) ステロイドスルファターゼインヒビターとしてのステロイド性化合物
US7078395B1 (en) Methods for treating or preventing cancer by preventing, inhibiting or arresting cell cycling
WO2008096155A1 (en) Composition comprising a glycolytic inhibitor and a ring system comprising a sulphamate group for the treatment of cancer
US20100197647A1 (en) Compounds that inhibit oestrone sulphatase; compositions thereof; and methods employing the same
AU2005225148B2 (en) Use
AU2533101A (en) Composition
ZA200108363B (en) Use.
EP1657247B1 (en) Steroidal compounds for inhibiting steroid sulphotase
EP1769799A2 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
HK1082258A1 (en) Oestrogen derivatives as inhibitors of steroid sulphatase
HK1082258B (en) Oestrogen derivatives as inhibitors of steroid sulphatase

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 28 APR 2020 BY CPA GLOBAL

Effective date: 20130315

EXPY Patent expired